GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China
Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.
On October 14, the official website of the China National Medical Products Administration (NMPA) reported that the new indication for lung cancer of the injection monoclonal antibody trastuzumab deruxtecan (Enhertu) applied by Daiichi Sankyo has been approved for marketing. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate developed jointly by Astrazeneca (AZN.US) and Daiichi Sankyo.
AstraZeneca Expanding R&D Pipeline in China
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing